KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) Research & Development (2016 - 2025)

Historic Research & Development for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Gilead Sciences' Research & Development fell 351.25% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 billion, marking a year-over-year increase of 322.52%. This contributed to the annual value of $5.9 billion for FY2024, which is 330.54% up from last year.
  • As of Q3 2025, Gilead Sciences' Research & Development stood at $1.3 billion, which was down 351.25% from $1.5 billion recorded in Q2 2025.
  • Over the past 5 years, Gilead Sciences' Research & Development peaked at $1.6 billion during Q4 2024, and registered a low of $1.1 billion during Q1 2021.
  • Moreover, its 5-year median value for Research & Development was $1.4 billion (2025), whereas its average is $1.3 billion.
  • Its Research & Development has fluctuated over the past 5 years, first tumbled by 1593.53% in 2021, then skyrocketed by 2767.7% in 2023.
  • Over the past 5 years, Gilead Sciences' Research & Development (Quarter) stood at $1.4 billion in 2021, then grew by 13.99% to $1.5 billion in 2022, then dropped by 9.04% to $1.4 billion in 2023, then increased by 16.55% to $1.6 billion in 2024, then dropped by 17.98% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q3 2025, $1.5 billion for Q2 2025, and $1.4 billion during Q1 2025.